Calla Lily Clinical Care
PrivateLast Round
Pre Seed
Jun 1, 2025
Total Funding Raised
$7.35M
Company Overview
Calla Lily Clinical Care is a medical device company that develops patented, leak-resistant intravaginal drug delivery platforms for women's health applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Calla Lily Clinical Care Comparables
Compare Calla Lily Clinical Care with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| LiGalli B.V. | 84% | |
| Gynica | 80% | |
| Evestra, Inc. | 79% |
Calla Lily Clinical Care Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Jun 1, 2025 | ||||
| Early Funding | May 13, 2025 | ||||
| Grant | Apr 3, 2025 | ||||
| Accelerator | Mar 26, 2025 | ||||
| Seed | Jan 1, 2025 | ||||
Seed | Mar 31, 2024 |
Key People
Founding team and executive leadership
Calla Lily Clinical Care Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Springboard Enterprises | Accelerator |
| National Institute for Health and Care Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 10, 2026
Partnered with Merck on an intravaginal drug delivery platform.
- Aug 29, 2025
Developing a novel vaginal platform technology for women's health.
Recent news
Latest coverage and updates
- receives_awardOct 22, 2026
At the 2026 BioUK Awards, Calla Lily Clinical Care Ltd receives the Best Early Stage Medtech CompanyAward, sponsored by Penningtons Manches Cooper, for its clinical-stage women’s health work developing an intravaginal drug-delivery platform targeting threatened miscarriage and IVF.
- receives_awardOct 22, 2026
Calla Lily Clinical Care Ltd receives the BioSeed 'One to Watch' Award, sponsored by EY, after winning two categories.
- hiresOct 7, 2026
Calla Lily Clinical Care Ltd appoints Mark Lubkeman to its board of directors
- signs_new_clientAug 11, 2026
Calla Lily Clinical Care Ltd signed new client Wellcome Leap Inc. on Aug 11th '26.
Calla Lily Clinical Care Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Calla Lily Clinical Care's valuation, stock price, and market status.
Is Calla Lily Clinical Care a public or private company?
Calla Lily Clinical Care is a private company.
What is the current stock price of Calla Lily Clinical Care?
Calla Lily Clinical Care is a private company, so its shares have no public market price. Caplight tracks Calla Lily Clinical Care's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Calla Lily Clinical Care worth (valuation)?
Valuation information for Calla Lily Clinical Care is not publicly available.
Can I buy Calla Lily Clinical Care stock?
Calla Lily Clinical Care shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Calla Lily Clinical Care's last funding round?
Calla Lily Clinical Care's most recent funding round was Pre Seed on June 1, 2025.
Who are the main investors in Calla Lily Clinical Care?
Key investors in Calla Lily Clinical Care include Innovate UK, Springboard Enterprises, National Institute for Health and Care Research.
Will Calla Lily Clinical Care IPO soon?
No public IPO plans have been announced for Calla Lily Clinical Care.
How can I track Calla Lily Clinical Care secondary market activity?
Caplight tracks bids, offers, and trades in Calla Lily Clinical Care's shares on secondary markets.